Savara Inc. $SVRA Shares Acquired by Rhumbline Advisers

Rhumbline Advisers grew its holdings in Savara Inc. (NASDAQ:SVRA) by 8.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 153,542 shares of the company’s stock after buying an additional 12,117 shares during the quarter. Rhumbline Advisers’ holdings in Savara were worth $425,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Savara by 24.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company’s stock worth $482,000 after purchasing an additional 31,168 shares during the last quarter. Millennium Management LLC increased its position in Savara by 71.8% during the fourth quarter. Millennium Management LLC now owns 482,263 shares of the company’s stock worth $1,481,000 after purchasing an additional 201,599 shares during the last quarter. D. E. Shaw & Co. Inc. increased its position in Savara by 314.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company’s stock worth $217,000 after purchasing an additional 53,547 shares during the last quarter. Farther Finance Advisors LLC increased its position in Savara by 25.3% during the first quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company’s stock worth $92,000 after purchasing an additional 6,532 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC increased its position in Savara by 20.8% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after purchasing an additional 3,035,164 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Trading Down 0.3%

NASDAQ SVRA opened at $3.48 on Wednesday. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $4.66. The stock has a market capitalization of $601.48 million, a PE ratio of -6.96 and a beta of 0.56. The firm has a 50 day moving average of $3.04 and a two-hundred day moving average of $2.80.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, research analysts expect that Savara Inc. will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Evercore ISI cut their price objective on shares of Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research report on Wednesday, May 28th. Oppenheimer raised their price objective on shares of Savara from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. HC Wainwright raised their price objective on shares of Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Wells Fargo & Company dropped their price target on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, May 28th. Finally, Guggenheim lifted their price target on shares of Savara from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.